Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NASDAQ:BWAY

Brainsway Q1 2026 Earnings Report

Brainsway logo
$16.42 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$16.70 +0.28 (+1.74%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Brainsway EPS Results

Actual EPS
N/A
Consensus EPS
$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

Brainsway Revenue Results

Actual Revenue
N/A
Expected Revenue
$14.63 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Brainsway Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Brainsway Earnings Headlines

BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283679/17676/en/brainsway-to-report-first-quarter-2026-financial-results-on-may-13-2026.html
BrainsWay: Competitive Threats Are Mounting
April 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4893958-brainsway-competitive-threats-are-mounting
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.tc pixel
May 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
April 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/15/3274325/17676/en/brainsway-highlights-growing-u-s-payer-support-for-nurse-practitioner-administered-transcranial-magnetic-stimulation-tms-therapy.html
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/13/3272440/17676/en/brainsway-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference.html
BrainsWay - Depositary receipt (BWAY) price target decreased by 59.41% to 0.05
April 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/brainsway-depositary-receipt-bway-price-target-decreased-by-5941-to-005/ar-AA20uKWj
See More Brainsway Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Brainsway? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Brainsway and other key companies, straight to your email.

About Brainsway

Brainsway (NASDAQ:BWAY) Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices. Brainsway has secured regulatory clearances in key markets, including U.S. Food and Drug Administration approvals for treatment-resistant major depressive disorder, obsessive-compulsive disorder, and smoking cessation. In addition to cleared indications, the company is pursuing clinical studies in areas such as migraine and substance use disorders to expand its therapeutic portfolio.

Founded in 2003 and headquartered in Jerusalem, Israel, Brainsway operates through subsidiaries and distribution partners across North America, Europe and the Asia-Pacific region. The company maintains a sales and support presence in the United States, including a facility in North Carolina, and collaborates with academic medical centers and independent clinics to facilitate training, research and patient access.

Brainsway’s leadership team brings together experts in neuroscience, clinical medicine and medical technology commercialization. The company continues to invest in research collaborations and real-world evidence initiatives aimed at demonstrating the long-term safety, efficacy and health-economic value of its Deep TMS solutions.

View Brainsway Profile
Earnings Tools